EGFR and non-small cell lung carcinoma: To further understand the benefit of BA in combination with gefitinib and osimertinib and to determine the molecular basis of the sensitization of primary TKI-resistant NSCLC cells to EGFR-TKIs, we investigated the effects of BA, gefitinib/osimertinib, and their cotreatment on EGFR bypass pathways [50].